Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs).

Férir G, Vermeire K, Huskens D, Balzarini J, Van Damme EJ, Kehr JC, Dittmann E, Swanson MD, Markovitz DM, Schols D.

Antiviral Res. 2011 Jun;90(3):200-4. doi: 10.1016/j.antiviral.2011.03.188. Epub 2011 Apr 8.

PMID:
21501631
2.

Combination of antiretroviral drugs as microbicides.

Balzarini J, Schols D.

Curr HIV Res. 2012 Jan 1;10(1):53-60.

PMID:
22264046
3.

In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.

Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD.

Antivir Ther. 2006;11(3):377-84.

PMID:
16759055
4.

Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.

Fung HB, Stone EA, Piacenti FJ.

Clin Ther. 2002 Oct;24(10):1515-48. Review.

PMID:
12462284
5.

Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.

Férir G, Huskens D, Palmer KE, Boudreaux DM, Swanson MD, Markovitz DM, Balzarini J, Schols D.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1513-23. doi: 10.1089/AID.2012.0026. Epub 2012 Jun 25.

6.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
7.

Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.

Kagan RM, Merigan TC, Winters MA, Heseltine PN.

Antivir Ther. 2004 Oct;9(5):827-8. No abstract available.

PMID:
15535422
8.

Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.

Schader SM, Colby-Germinario SP, Schachter JR, Xu H, Wainberg MA.

AIDS. 2011 Aug 24;25(13):1585-94. doi: 10.1097/QAD.0b013e3283491f89.

PMID:
21633286
9.

K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.

Miller MD, Margot N, McColl D, Cheng AK.

AIDS. 2007 Jan 11;21(2):265-6. No abstract available.

PMID:
17197831
10.

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21.

PMID:
12792350
11.
12.

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.

Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.

J Med Virol. 2007 Feb;79(2):105-10.

PMID:
17177308
13.
14.

[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].

Pulido F, Fiorante S.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:13-8. Review. Spanish.

PMID:
19195433
15.

Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.

Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.

Antivir Ther. 2006;11(6):827-30.

PMID:
17310827
16.

[Tenofovir: pharmacology and interactions].

Azanza JR, García Quetglas E, Sádaba B, Gómez-Giu A.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:2-6. Review. Spanish.

PMID:
19195431
17.

Tenofovir disoproxil fumarate.

Gallant JE, Deresinski S.

Clin Infect Dis. 2003 Oct 1;37(7):944-50. Epub 2003 Sep 12.

PMID:
13130407
18.

K65R, TAMs and tenofovir.

Miller MD.

AIDS Rev. 2004 Jan-Mar;6(1):22-33. Review.

PMID:
15168738
19.

The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications.

Férir G, Petrova MI, Andrei G, Huskens D, Hoorelbeke B, Snoeck R, Vanderleyden J, Balzarini J, Bartoschek S, Brönstrup M, Süssmuth RD, Schols D.

PLoS One. 2013 May 28;8(5):e64010. doi: 10.1371/journal.pone.0064010. Print 2013.

20.

Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.

Férir G, Palmer KE, Schols D.

Virology. 2011 Sep 1;417(2):253-8. doi: 10.1016/j.virol.2011.07.004. Epub 2011 Jul 28.

Supplemental Content

Support Center